You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

single arm phase 2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
May 24, 2023

Rectal Cancer Trial in Osaka (radiation, drug, procedure)

Recruiting
  • Rectal Cancer
  • Radiation
  • +2 more
  • Osaka, Japan
  • +1 more
Jul 1, 2023

Lung Cancer Trial (Sacituzumab Govitecan, Pembrolizumab)

Not yet recruiting
  • Lung Cancer
  • (no location specified)
Sep 20, 2023

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical

Recruiting
  • Cervical Cancer
  • +2 more
  • Treatment Group
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 9, 2023

Langerhans Cell Histiocytosis, LCH Trial (FCN-159)

Not yet recruiting
  • Langerhans Cell Histiocytosis
  • LCH
  • (no location specified)
Aug 15, 2023

NSCLC Trial in Changsha (Sugemalimab and Chemotherapy)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sugemalimab and Chemotherapy
  • Changsha, China
    Hunan Cancer Hospital
Jul 7, 2023

Colorectal Cancer, Liver Metastases Trial in Hangzhou (Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion)

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastases
  • Hangzhou, Zhejiang, China
    the Second Affiliated Hospital of Medical College of Zhejiang Un
Jun 7, 2023

Atopic Dermatitis Trial (CM310)

Not yet recruiting
  • Atopic Dermatitis
  • CM310
  • (no location specified)
Oct 30, 2023

Chordoma, Chemo Effect Trial in Beijing (camrelizumab and apatinib)

Recruiting
  • Chordoma
  • Chemotherapy Effect
  • camrelizumab and apatinib
  • Beijing, Beijing, China
    BEIJING
Nov 14, 2023

Hepatocellular Carcinoma Trial in Guangzhou (TACE-HACI, plus atezolizumab-bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • TACE-HACI, plus atezolizumab-bevacizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 20, 2023

Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory Trial (Glofitamab, Pirtobrutinib, Obinutuzumab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
Apr 18, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

NSCLC With STK11/LKB1 Mutation Trial in New York (Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication,

Not yet recruiting
  • Non-small Cell Lung Cancer With STK11/LKB1 Mutation
  • Daratumumab and Hyaluronidase-fihj
  • +2 more
  • New York, New York
    NYU Langone Health
Mar 29, 2023

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,

Recruiting
  • The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
  • Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
  • Hanzhou, Zhejiang, China
    Lulu Liu
Jul 14, 2023

Pancreatic Adenocarcinoma Metastatic Trial in Nanjing (Penpulimab, Anlotinib, Nab paclitaxel)

Recruiting
  • Pancreatic Adenocarcinoma Metastatic
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 18, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Withdrawn
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jun 1, 2023

Muscle-Invasive Bladder Carcinoma Trial in Milan (Nivolumab + Nab-paclitaxel, Nivolumab)

Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Milan, MI, Italy
    Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and
Mar 28, 2022

HER2-positive Breast Cancer Trial in Ireland (trastuzumab deruxtecan (T-DXd) (IV))

Not yet recruiting
  • HER2-positive Breast Cancer
  • trastuzumab deruxtecan (T-DXd) (IV)
  • Galway, Connaught, Ireland
  • +4 more
Jan 24, 2023

Glioblastoma, IDH-wildtype, Metformin, Malignancies Trial in Milan (Metformin)

Not yet recruiting
  • Glioblastoma, IDH-wildtype
  • +2 more
  • Milan, Italy
    Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Mil
Jun 26, 2023

The GOAL27-6 Study

Recruiting
  • Head and Neck Cancer
    • Northwood, Middlesex, United Kingdom
      Mount Vernon Cancer Centre
    May 5, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Feb 26, 2023

    Familial Mediterranean Fever Trial (RIST4721)

    Recruiting
    • Familial Mediterranean Fever
    • Haifa, Israel
    • +4 more
    Jan 6, 2023

    HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

    Recruiting
    • HER2-negative Breast Cancer
    • +5 more
    • Camrelizumab with vinorelbine and cisplatin
    • Beijing, Beijing, China
      Peking University First Hospital
    Oct 15, 2022

    Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

    Recruiting
    • Hypomethylating Agent
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Jiao Tong University School of Medicine Affilated Shang
    May 2, 2023